

# Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells

Renáta Váraljai,<sup>1,7</sup> Abul B.M.M.K. Islam,<sup>1,2,3,7</sup> Michael L. Beshiri,<sup>1</sup> Jalees Rehman,<sup>4,5</sup> Nuria Lopez-Bigas,<sup>2,6</sup> and Elizaveta V. Benevolenskaya<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois 60607, USA; <sup>2</sup>Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, Barcelona Biomedical Research Park, Universitat Pompeu Fabra, Barcelona 08003, Spain; <sup>3</sup>Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka 1000, Bangladesh; <sup>4</sup>Section of Cardiology, Department of Medicine, <sup>5</sup>Department of Pharmacology, University of Illinois at Chicago, Chicago, Illinois 60612, USA; <sup>6</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain

The retinoblastoma tumor suppressor protein pRb restricts cell growth through inhibition of cell cycle progression. Increasing evidence suggests that pRb also promotes differentiation, but the mechanisms are poorly understood, and the key question remains as to how differentiation in tumor cells can be enhanced in order to diminish their aggressive potential. Previously, we identified the histone demethylase KDM5A (lysine [K]-specific demethylase 5A), which demethylates histone H3 on Lys4 (H3K4), as a pRB-interacting protein counteracting pRB's role in promoting differentiation. Here we show that loss of *Kdm5a* restores differentiation through increasing mitochondrial respiration. This metabolic effect is both necessary and sufficient to induce the expression of a network of cell type-specific signaling and structural genes. Importantly, the regulatory functions of pRB in the cell cycle and differentiation are distinct because although restoring differentiation requires intact mitochondrial function, it does not necessitate cell cycle exit. Cells lacking *Rb1* exhibit defective mitochondria and decreased oxygen consumption. *Kdm5a* is a direct repressor of metabolic regulatory genes, thus explaining the compensatory role of *Kdm5a* deletion in restoring mitochondrial function and differentiation. Significantly, activation of mitochondrial function by the mitochondrial biogenesis regulator Pgc-1 $\alpha$  (peroxisome proliferator-activated receptor  $\gamma$ -coactivator 1 $\alpha$ ; also called PPARGC1A) a coactivator of the *Kdm5a* target genes, is sufficient to override the differentiation block. Overexpression of Pgc-1 $\alpha$ , like *KDM5A* deletion, inhibits cell growth in *RB*-negative human cancer cell lines. The rescue of differentiation by loss of *KDM5A* or by activation of mitochondrial biogenesis reveals the switch to oxidative phosphorylation as an essential step in restoring differentiation and a less aggressive cancer phenotype.

[Keywords: pRB; differentiation; mitochondria; KDM5A; RBP2; histone methylation]

Supplemental material is available for this article.

Received April 16, 2015; revised version accepted August 6, 2015.

The functional inactivation of the tumor suppressor pRB results in an inability of cells to respond to growth inhibitory signals and forms the basis of multiple cancers. *Rb1* deficiency in mice (*Rb1*<sup>-/-</sup>) was found to be embryonic-lethal, and each tissue expressing a high level of pRb showed evidence of not only continuous cell proliferation but also defective terminal differentiation (Macleod 1999). However, there is a lack of consensus on whether the differentiation failure is simply a consequence of the cell cycle defect or even a cell-nonautonomous effect. Moreover,

the idea that the main function of pRB is regulation of E2F-dependent genes and cell cycle exit (Frolov and Dyson 2004) was appealing, as it might explain why pRb is so important for tumor suppression. However, analysis of *Rb1*<sup>-/-</sup> embryos that were rescued from embryonic lethality with either wild-type placentas or low levels of the *Rb1* gene showed marked skeletal muscle defects at birth (Zacksenhaus et al. 1996; de Bruin et al. 2003; MacPherson et al. 2003; Wu et al. 2003), thus underscoring the

<sup>7</sup>These authors contributed equally to this work.

Corresponding author: evb@uic.edu

Article published online ahead of print. Article and publication date are online at <http://www.genesdev.org/cgi/doi/10.1101/gad.264036.115>.

© 2015 Váraljai et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License [Attribution-NonCommercial 4.0 International], as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

functional importance of pRb as a regulator of muscle differentiation and development. Consistent with *in vivo* findings, *Rb1*<sup>-/-</sup> mouse embryonic fibroblasts (MEFs) did not respond to the forced expression of the myogenic differentiation antigen (MyoD) (Novitsch et al. 1996). Lysine (K)-specific demethylase 5A (KDM5A; also known as RBP2 and JARID1A) was isolated in a genetic screen with pRb derivatives deficient in interaction with E2F but retaining the ability to induce differentiation, suggesting that induction of differentiation is an E2F-independent pRb function (Benevolenskaya et al. 2005). Importantly, pRb mutants that failed to form complexes with KDM5A were also unable to induce differentiation. Surprisingly, the loss of this nonmyogenic epigenetic factor was able to rescue the differentiation defect. Specifically, loss of *Kdm5a* by knockdown or knockout in cells defective in pRb was sufficient to resume expression of markers associated with senescence and myogenic or adipogenic differentiation, as it increased transcription factor (TF) activity and restored gene expression, thus phenocopying the reintroduction of wild-type pRb (Benevolenskaya et al. 2005; Lin et al. 2011). These studies highlight the importance of the RB/KDM5A branch of the pathway in regulating differentiation. However, associating specific genes and biological processes regulated by pRb and KDM5A with differentiation rescue would be critical for understanding the link between differentiation and tumor suppression. This would establish whether differentiation induction is independent of cell cycle regulation and might lead the way to the design of new strategies counteracting malignant transformation.


## Results

### *Kdm5a* loss in *Rb*-negative cells rescues differentiation but not permanent cell cycle withdrawal

To study how pRb-mediated differentiation is rescued by *Kdm5a* loss, we adopted differentiation assays in MEFs isolated from *Rb1* and *Kdm5a* knockout animals. MEFs were induced for myogenic differentiation using transduction with adenoviral (Adeno) or lentiviral (Lenti) MyoD and incubation in differentiation medium (DM) (Fig. 1A). A decrease in *Kdm5a* phenocopies reintroduction of pRb in myotube formation, as described previously by staining induced MEFs with DAPI and the late marker of myogenic differentiation myosin heavy chain (MyHC) (Benevolenskaya et al. 2005; Lin et al. 2011). However, pRb is essential for cell cycle exit in myoblasts, activating at least three distinct chromatin-based regulatory mechanisms (Blais et al. 2007; van Oevelen et al. 2008), and KDM5A cooperates with rather than opposes RB family protein complexes in repressing cell cycle genes during differentiation (Beshiri et al. 2012). Induced MEFs exhibit three hallmarks of differentiation: up-regulation of muscle gene expression, cell cycle arrest, and myoblast fusion with formation of multinucleated myotubes. To test whether *Kdm5a* loss fully phenocopies pRb during differentiation, cells were stained for MyHC and DAPI for detection of multinucleated myotubes and with EdU as

an indicator of S-phase entry. Consistent with the dependence of myogenic differentiation on the *Rb1* status (Novitsch et al. 1996), the three hallmarks of myogenic differentiation were impaired in *Rb1*<sup>-/-</sup> MEFs (Fig. 1B). In particular, the MyHC protein level was negligible in *Rb1*<sup>-/-</sup> but highly elevated in the wild-type genotype (Fig. 1C). Transduction of *Rb1*<sup>-/-</sup> MEFs with a lentiviral pRb construct restored differentiation back to normal (Supplemental Fig. 1A–D). MEFs are mesenchymal stem cell-like multipotent progenitor cells capable of differentiation into several lineages, including bone, cartilage, adipose, and muscle. To test whether pRb function requires inhibition of *Kdm5a* during differentiation progression in cells committed to myogenic lineage, we used C2C12 cells, representing myogenic precursor cells. Transduction of C2C12 cells with *Rb1* shRNAs blocked differentiation progression (Supplemental Fig. 1E–G). The block was released by simultaneous transduction with *Kdm5a* shRNA. Taken together, these experiments demonstrated that *Kdm5a* loss rescues *Rb*-dependent differentiation in cells with the properties of multipotent progenitors or committed progenitors.

In order to identify molecular features of rescued myotubes, we performed an RNA sequencing (RNA-seq) experiment. To exclude the possibility that cells failing differentiation induction would obscure the results of analysis in total cell population, a pure population of myotubes was prepared using a size fractionation procedure (Supplemental Fig. 1H). RNA species for a majority of genes annotated to the gene ontology (GO) “muscle system process” were induced at a high level in both wild-type (WT-myo) and double knockout (*Rb1*<sup>-/-</sup> and *Kdm5a*<sup>-/-</sup>; DKO-myo) MEFs (Supplemental Table 1). In WT-myo, 34,000 RNA-seq counts were detected for the myogenin (*Myog*) gene, which is expressed early during myogenesis (Berkes and Tapscott 2005), and 169,000 counts were detected for the *Myh3* gene expressed in embryonic muscle, which was the most abundant MyHC expressed in induced MEFs. In contrast, genes encoding transcriptional activators E2F1–3 or cyclins A and E reached only up to 700 counts, which was consistent with cell withdrawal from the cell cycle during differentiation. A comparison between induced *Rb1*<sup>-/-</sup> MEFs and WT-myo showed that 2766 genes were decreased at log<sub>2</sub> 0.76 in *Rb1*<sup>-/-</sup> MEFs. Strikingly, 2426 of these genes experienced more than half (log<sub>2</sub> 0.38) restoration of expression level in DKO-myo. To further define biological processes that were deregulated in the *Rb1*<sup>-/-</sup> genotype but rescued in DKO-myo, we performed GO enrichment analysis. Analysis of the 2766 genes that were decreased in *Rb1*<sup>-/-</sup> cells showed significant overrepresentation in the GO “muscle system process” (Fig. 1D; Supplemental Table 2). The expression levels for many muscle genes were similar in DKO-myo when compared with the WT-myo while different from *Rb1*<sup>-/-</sup> cells (Fig. 1E; Supplemental Table 1), suggesting that the myogenic transcription program was significantly rescued upon concomitant deletion of *Kdm5a*. Moreover, there was no delay in induction of differentiation markers in double-knockout MEFs. In fact, double-knockout cells showed more robust expression of



**Figure 1.** *Kdm5a* loss in *Rb*-negative cells phenocopies specific functions of pRB. (A) Conversion of MEFs to myotubes using adenoviral or lentiviral expression of MyoD. Hereafter, this treatment is referred to as “induced” cells. (B) Induced MEFs show differences in muscle gene expression, cell cycle arrest, and multinucleation depending on *Rb1* status. MEFs were isolated from wild-type, *Kdm5a*<sup>-/-</sup>, and double-knockout littermates and *Rb1*<sup>-/-</sup> embryos at the same genetic background as described previously (Lin et al. 2011). In order to convert them to myotubes, cells were first transduced with Adeno-MyoD and induced in DM for 96 h. To identify the differentiated cells, immunocytochemical (ICC) staining was performed for the late marker of differentiation MyHC. To assess permanent cell cycle withdrawal, cells were stimulated in high-serum medium and stained with nucleotide analog EdU and nuclear stain DAPI. Cells were visualized by confocal microscopy. (C) The expression level of MyHC is fully rescued in the double knockout. Immunoblot analysis of cell lysates prepared from MEFs of the indicated genotypes transduced with Lenti-MyoD and induced for 120 h. (D) *Kdm5a* loss results in rescued expression in gene groups associated with specific functions. Enrichment analysis for gene relations to gene ontology (GO) biological process terms is shown for the gene sets derived from an RNA sequencing (RNA-seq) experiment in induced MEFs with different *Rb1* and *Kdm5a* statuses and from a chromatin immunoprecipitation (ChIP) combined with deep sequencing (ChIP-seq) assay in *Kdm5a*<sup>+/+</sup> embryonic stem cells (for gene lists, see Supplemental Table 2) (this study; Beshiri et al. 2012). *P*-values are delineated in a colored heat map, where color-coding indicates the degree of significance: highest significance (red) to least significance (orange) and nonsignificant (values are in gray). Data are shown for GOs representing large gene sets (>20 genes) and with *P*-values of  $\leq 10^{-5}$  in *Rb1*<sup>-/-</sup> MEFs and include all GOs that are also highly significantly enriched in rescued *Kdm5a* targets. (E) RNA-seq count values for genes in GO biological process terms “muscle system” and “cell cycle” and GO cellular location term “mitochondrion.” RNA-seq count values (see the Supplemental Material) are shown (for genes with  $\geq 50$  counts) as a heat map relative to the mean count value in wild type (WT-my0; 305 counts).

myogenin than wild-type cells as early as 12 h after induction, and it persisted longer (Supplemental Fig. 2A–C). Chromatin immunoprecipitation (ChIP) experiments showed that MyoD was very highly enriched at the *Myog* promoter when compared with the control unbound intergenic region *Igr2* at 24 h, which was similar to the time it is recruited to the *Myog* in mouse C2C12 myoblasts (Supplemental Fig. 2D,E).

While the muscle genes were significantly rescued in DKO-myo, cell cycle-related GOs were overrepresented among differentially expressed (DE) genes between DKO-myo and WT-myo (Fig. 1D). *E2f1-3*, *cyclins*, and other GO “cell cycle” genes were as highly expressed in double-knockout myotubes as in induced *Rb1*<sup>-/-</sup> fibroblasts (Fig. 1E; Supplemental Table 1). These data suggested that the deletion of *Kdm5a* in *Rb1*<sup>-/-</sup> MEFs rescued two hallmarks of myogenic differentiation; however, it did not rescue cell cycle withdrawal. Indeed, staining for EdU incorporation and the mitotic marker H3pS10 indi-

cated that both induced *Rb1*<sup>-/-</sup> and double-knockout MEFs had active DNA synthesis and progressed through mitosis (Fig. 1B; Supplemental Fig. 3). In fact, there was a small increase in cell cycle entry in induced double-knockout compared with *Rb1*<sup>-/-</sup> MEFs, consistent with cooperative effects between KDM5A and pRB proteins (Beshiri et al. 2012), where pRB is likely playing a dominant role, as the loss of *Kdm5a* alone did not result in a cell cycle defect. This establishes KDM5A as a downstream target of pRB, regulating differentiation independently from cell cycle exit.

#### *pRB* is required for activation of genes encoding mitochondrial proteins

In order to distinguish direct and indirect consequences of *Kdm5a* loss, expression differences were studied in the genes with the locations closest to the *Kdm5a* peaks. As muscle gene and cell cycle gene expression coordinately

changes during myogenic differentiation, we tested a set of developmental genes in which Kdm5a binds either proximal to the transcription start site (TSS) or in a distal regulatory region in proliferating cells and a set of cell cycle genes in which Kdm5a binds specifically during differentiation (Beshiri et al. 2012). RNA-seq and RT-qPCR analysis showed that none of the tested genes was rescued in double knockout and instead remained at the levels seen in *Rb1*<sup>-/-</sup> cells (see RNA-seq data GSE53528 for full gene list) (Fig. 2A). Some of these genes are related to myogenic differentiation, as MyoD bound to the same regions as Kdm5a in *Ass1*, *Mstn*, *Gdf15*, and *Glis2* genes (when ENCODE/California Institute of Technology MyoD data from C2C12 myoblasts are compared with our CHIP-seq [ChIP combined with deep sequencing] data [GSE28343]). Conversely, the muscle genes that were decreased in *Rb1*<sup>-/-</sup> cells and significantly rescued in DKO-my0 (Fig. 1E) are not known to be Kdm5a targets. Notably, the muscle genes were activated in the induced wild-type or double-knockout MEFs at least at the level of their activation in differentiating C2C12 myoblasts (Supplemental Figs. 4, 5A). In contrast to the more than log<sub>2</sub> 10-fold increase in expression of muscle genes, Kdm5a-bound developmental genes either intermittently or progressively decreased in expression during differentiation, falling far behind the median expression value, along with the Kdm5a/Rb/E2f targets *Nusap1* and *Kif2c* (Supplemental Fig. 4B,C). Therefore, pRb-mediated differentiation does not require the activity of developmental genes occupied by Kdm5a.


We were surprised to find that the GOs that were most highly significantly overrepresented among rescued genes along with the muscle system related to functions in the mitochondrion (Fig. 1D). These included 80 genes related to the generation of precursor metabolites and energy and respiratory chain complex (RC) subunits and involved in ATP metabolism, mitochondrial dynamics, and architecture (Fig. 2B; Supplemental Table 1). Monitoring gene expression dynamics showed that genes encoding mitochondrial proteins that are bona fide Kdm5a targets increased in expression early during differentiation compared with the muscle signaling genes (e.g., *Myog*, *Mef2c* [myocyte enhancer factor 2c], and *Ckm*) and structural genes (e.g., *Myh3*, *My6*, *Des*, *Tnni1*, and *Tnnc2*) (Fig. 2C; Supplemental Fig. 5A,B; Supplemental Table 1). These genes represented not only myotube-specific isoforms such as the RC subunit *Cox6a2*, which displayed an almost log<sub>2</sub> sevenfold rescue in DKO-my0, but also the ubiquitously expressed subunits. For example, the gene involved in mitochondrial fusion (*Mfn2*) and genes that we tested for each of the RCs exhibited increased expression levels in all induced MEFs except for *Rb1*<sup>-/-</sup> (Fig. 2C). Notably, the increase was also seen at the protein level, as exemplified by the *Mfn2* increase in induced C2C12 cells and all MEFs except for *Rb1*<sup>-/-</sup> (Supplemental Fig. 5C,D). The decrease in the *Mfn2* protein level was relevant to the pRb/Kdm5a axis, as *Kdm5a* shRNA mitigated the effect of acute loss of pRb by increasing *Mfn2* expression (Supplemental Fig. 1G). To confirm that activation of genes encoding mitochondrial proteins accompanies dif-

ferentiation into other cell types besides myotubes, MEFs were also induced to undergo adipogenic differentiation. Double-knockout MEFs displayed rescued *Mfn2* and RC gene expression at 24 h of differentiation, paralleling expression changes of adipogenesis markers *Agpat2*, *Fabp4*, and *Cebpa* and followed by lipid accumulation (Supplemental Fig. 6). These data highlighted that mitochondrial function was central to the cell type-specific gene expression and differentiation rescue induced by the *Kdm5a* loss.


In order to identify direct effectors of pRb-mediated differentiation, we analyzed the whole-genome distribution of pRB (Chicas et al. 2010) with respect to Kdm5a distribution (Beshiri et al. 2012). Kdm5a occupied 651 pRB target genes ( $\chi^2 = 294.27$ ;  $P < 10^{-16}$ ). A statistical test for binding of both proteins at the promoter and 5' untranslated regions (UTRs) showed a *P*-value of  $< 10^{-322}$ , suggesting that pRb and Kdm5a are frequently colocalized at promoters. When enrichment analysis was run on the overlap, we observed that the top enriched ( $P < 10^{-15}$ ) GO was "mitochondrion" (Fig. 2D; Supplemental Table 3). Consistent with the observation that almost one-third of Kdm5a targets are shared with E2f4 (Beshiri et al. 2012), some mitochondrial genes were occupied by E2f4. CHIP experiments in induced MEFs showed that pRb becomes enriched at TSSs of the genes involved in mitochondrial dynamics (*Mfn2* and *Opa1*) as well as genes encoding RC subunits, while Kdm5a binding to some of these genes decreased concomitantly with pRb recruitment (Fig. 2E). These results demonstrate that Kdm5a directly regulates genes encoding mitochondrial proteins and suggests that, during differentiation, a decrease in Kdm5a binding activates these genes.

#### *Kdm5a* catalytic activity is involved in inhibition of myogenic differentiation

To test whether KDM5A inhibition of differentiation is dependent on KDM5A demethylase activity, we examined the double-knockout cells transduced with a lentiviral construct expressing wild-type or catalytic domain mutant KDM5A. The mutant was similar to the wild type in expression level and was properly localized to the nucleus (Fig. 3A; Supplemental Fig. 7). Only the cells with reintroduced wild-type KDM5A evaded their ability to differentiate and behaved similar to *Rb1*<sup>-/-</sup> MEFs (Fig. 3B–D; Supplemental Fig. 7B,C). Transduction with wild-type KDM5A, but not with the catalytic domain or frameshift KDM5A mutants, resulted in highly significantly decreased numbers of MyHC- and EdU-positive cells and loss of expression of myogenic genes *Ckm*, *Tnnc2*, and *Tnni2*. As the double-knockout MEFs have an increased global level of H3K4 methylation compared with the MEFs with functional Kdm5a (Beshiri et al. 2012), one possibility is that inducing more active chromatin generally would be sufficient to promote differentiation. However, histone deacetylase (HDAC) inhibitors sodium butyrate and TSA were unable to rescue differentiation defects in *Rb1*<sup>-/-</sup> MEFs (Fig. 3E). These experiments



**Figure 2.** *Kdm5a* loss in *Rb*-negative cells restores expression of muscle genes and *Kdm5a* targets with mitochondrial functions. (A) Myogenic markers but not differentiation and cell cycle genes occupied by *Kdm5a* are rescued in double knockout. MEFs of four different genotypes were induced for 72 h. The expression levels of the myogenic markers and *Kdm5a* targets (with *Kdm5a* location in a distal or proximal promoter region) with function in differentiation or cell cycle were determined by RT-qPCR analysis. The data were normalized to the *Gapdh* level and are presented relative to the wild type. Mean  $\pm$  standard error of the mean (SEM) for  $n = 2$  RT-qPCR replicates. (B) The list of rescued genes contains many *Kdm5a* targets in the GO “mitochondrion” but not in the “muscle system.” Genes in the mitochondrion are grouped based on their function: generation of energy, ribosome, respiratory chain complex I–V (RCI–V), ATP metabolism, mitochondrial dynamics, or architecture. (C) Activation of genes encoding mitochondrial components failed in *Rb1*<sup>-/-</sup> MEFs but were restored in double knockout back toward wild-type levels. MEFs were induced to differentiate for 0, 24, and 96 h. The expression of genes randomly chosen from the lists of *Kdm5a* targets with functions in the mitochondrion was analyzed at each time point in each genotype. RT-qPCR data was normalized to spike controls and is shown as a fold change relative to the wild type at 0 h for each gene. Mean  $\pm$  SEM for  $n = 3$  RT-qPCR replicates. The statistical significance for the condition double knockout compared with *Rb1*<sup>-/-</sup> at 96 h was determined by the Student’s *t*-test: (\*) *P*-value  $\leq 0.005$ ; (\*\*) *P*-value  $\leq 0.001$ . (D) Enrichment analysis reveals mitochondrion as the top GO term for common targets of pRb and *Kdm5a*. Top GOs are presented for overlapping genes, with *P*-values shown for both overlapping and nonoverlapping genes in a heat map. The overlap between pRb targets and *Kdm5a* targets is enriched in the GO term “mitochondrion.” A Venn diagram shows the number of genes in the GO “mitochondrion” between pRb and *Kdm5a* and with E2f4. (E) Genes with functions in the mitochondrion are direct targets of both pRb and *Kdm5a*. ChIP experiments in *Rb1*<sup>-/-</sup> MEFs that were transduced with Lenti-Flag-pRb and grown as proliferating, growth-arrested (0 h), or induced for 24 h. The ChIP antibodies used were Flag and anti-KDM5A. *Igr2* is an intergenic control region. Mean  $\pm$  SEM for  $n = 2$  ChIPs.



**Figure 3.** Kdm5a catalytic activity is required for the inhibition of myogenic differentiation. (A) Expression level of KDM5A derivatives. The immunoblots were probed with the anti-KDM5A antibody and with  $\alpha$ -tubulin antibody as a loading control. (B) KDM5A inhibition of differentiation is dependent on its demethylase activity. ICC was performed as in Figure 1B in induced double-knockout cells that were transduced with different KDM5A derivatives, including the frameshift control. (C) Analysis of MyHC expression and cell cycle arrest in double-knockout cells prepared as in B. Quantification of MyHC-positive cells and cells that re-entered the cell cycle, marked by Edu, was performed relative to the total number of cells. In order to avoid artifacts of chromosome segregation (Manning et al. 2010) and nuclear duplication, which is common to *Rb*-deficient myocytes (Ciavarrá et al. 2011), only MyHC-positive cells containing more than two nuclei and lacking obvious aneuploidy were counted. Mean  $\pm$  SEM for  $n = 4$  replicate wells from three representative experiments is shown. (ns)  $P > 0.1$ ; (\*)  $P < 0.02$ ; (\*\*)  $P < 0.001$ ; (\*\*\*)  $P < 0.0001$ , calculated relative to the frameshift control. (D) Muscle gene expression is dependent on KDM5A demethylase activity. Double-knockout cells expressing different KDM5A derivatives were induced for 72 h. RNA was isolated, and transcript levels were determined relative to the frameshift control by RT-qPCR. The data are presented as the mean  $\pm$  standard deviation (SD) of RT-qPCR replicates ( $n = 2$ ) from a representative experiment. (\*\*)  $P$  value  $\leq 0.005$  is shown relative to the frameshift control. Gene expression was normalized relative to the geometrical mean of two spike controls. (E) Inducing more active chromatin with HDAC inhibitors does not rescue differentiation. *Rb1*<sup>-/-</sup> cells were induced in the presence of 5 mM sodium butyrate or 50 nM TSA for the first 24 h and in DM for the total of 72 h and were compared with the control DMSO-treated cells. (F) Kdm5a loss increases H3K4me3 at the *Mfn2* TSS region. Genome browser view of the *Mfn2* gene region at 10-kb and 500-base-pair (bp) scale. The TSS region is depicted by RNA polymerase II (Pol II) and Kdm5a occupancy and H3K4me3 enrichment. (G) H3K4me3 enrichment is increased at the *Mfn2* TSS Kdm5a peak in double-knockout compared with wild-type MEFs before induction of differentiation. ChIP was performed in 0-h MEFs. (H) The *Mfn2* TSS region displays increasing H3K4me3 enrichment after the induction of myogenic differentiation in MEFs. ChIP was performed in MEFs transduced as in Figure 2E, and data are shown for three amplicons (1, 2, and 3) covering the *Mfn2* TSS region, as presented at 500-bp scale in F. In G and H, mean  $\pm$  SEM for  $n = 2$  ChIP assays.

directly linked the inhibitory KDM5A function in differentiation to its demethylase activity.

Kdm5a-binding peaks lie within TSS regions overlapping with H3K4me3 peaks (Beshiri et al. 2012). As investigating differences in H3K4me3 around Kdm5a peaks is informative for identification of the genes involved, we performed a H3K4me3 ChIP-seq assay in *Kdm5a*<sup>fl/fl</sup> embryonic stem cells with deleted flox/flox alleles and the cells without a deletion. Enrichment analysis of genes in re-

gions demonstrating increased H3K4me3 levels in cells with *Kdm5a* deletion showed that, again, the mitochondrial functions were highly enriched (Fig. 1D). The *Mfn2* TSS region showed a peak of Kdm5a correlating with enriched H3K4me3, which further increased (1.4-fold change,  $P < 10^{-4}$ ) in *Kdm5a*<sup>-/-</sup> cells (Fig. 3F). Quantitation of H3K4me3 enrichment at the Kdm5a peak using ChIP-qPCR experiments showed an increase in MEFs lacking *Kdm5a* even in uninduced condition (Fig. 3G), correlating


with an increase in the *Mfn2* transcript level (Fig. 2C). This result is consistent with the data that *MFN2* promoter activity is regulated by KDM5A through H3K4me3 demethylation in human osteosarcoma SAOS-2 cells (Lopez-Bigas et al. 2008). ChIP-qPCR experiments using three different primer pairs in the *Mfn2* TSS regions showed that the H3K4me3 enrichment increased in a broad genomic region as early as 12 h in induced MEFs (Fig. 3H). Therefore, pRb and Kdm5a binding to genes encoding mitochondrial proteins likely plays a regulatory role during differentiation.

#### *Kdm5a* loss rescues the mitochondrial defect

Consistent with the gene expression changes, MEFs of the four genotypes undergoing differentiation displayed profound differences in mitochondrial mass and morphology. Analysis of the immunocytochemical (ICC) confocal microscopy images for the cytochrome c oxidase (RCIV) component Cox IV as well as the electron microscopy (EM) data revealed an increased number but decreased size of mitochondria in *Rb1*<sup>-/-</sup> cells (Fig. 4A,B). The defect was especially prominent in the induced condition, when mitochondrial mass and morphology (spheres/rods and tubules versus dense tubules and large spheres) were visualized by ICC for Cox IV or staining with MitoTracker, which covalently binds to mitochondrial proteins (Supplemental Fig. 8). This suggested that mitochondrial networking is affected by *Rb1* loss, resulting in mitochondrial fragmentation. On the other hand, concomitant loss of Kdm5a rescued the observed changes in mitochondrial mass and morphology (Fig. 4A,B; Supplemental Figs. 7D, 8). To further characterize the difference in mitochondria between the *Rb1*<sup>-/-</sup> and other genotypes, the mitochondrial protein levels were studied by immunoblot analysis. The levels of Cox IV and *Mfn2* were very low in induced *Rb1*<sup>-/-</sup> cells compared with the wild type but increased back to the normal level in double knockout (Fig. 4C; Supplemental Fig. 5D). The difference between *Rb1*<sup>-/-</sup> and double knockout was observed in the level of proteins encoding Kdm5a target genes—i.e., *Cox IV* and *Mfn2*—but not in proteins encoding genes not bound by Kdm5a, such as the outer mitochondrial membrane protein *Vdac1*. It should also be pointed out that only specific mitochondrial processes were rescued in double knockout (Fig. 2B). For example, genes associated with apoptosis or glutamine metabolism—such as manganese superoxide dismutase *sod2*, known to protect cells against oxidative stress, or the transglutaminase *tgm2*—were not rescued (see RNA-seq data GSE53528 for a full gene list).

To assess whether double-knockout MEFs have appropriately assembled RCs capable of oxidative phosphorylation, oxygen consumption was measured using a Seahorse Bioscience extracellular flux analyzer. A comparison of induced MEFs of four different genotypes showed that both the basal oxygen consumption rate and the maximal respiratory capacity as determined by addition of the uncoupler FCCP increased in all differentiating MEFs in

contrast to *Rb1*<sup>-/-</sup> MEFs (Fig. 4D). The basal respiration was higher in all cells lacking *Kdm5a*, consistent with the increased levels of genes encoding mitochondrial proteins (Figs. 2C, 4C). The DKO-myo cells had a markedly high maximal respiratory capacity upon induction, thus demonstrating that loss of *Kdm5a* not only reversed the depletion of the mitochondrial reserve by *Rb1* loss but even enhanced the respiratory reserve capacity. In a glycolysis stress test, loss of *Kdm5a* resulted in a higher basal extracellular acidification rate (ECAR), and glucose addition triggered a further increase (Supplemental Fig. 9A). However, glycolytic capacity decreased in induced wild-type and *Kdm5a*<sup>-/-</sup> cells to the *Rb1*<sup>-/-</sup> level, suggesting that it is unlikely to be a major contributor to the differentiation rescue. The ECAR increase indicated that added glucose metabolized to lactate. We inhibited oxidative phosphorylation with oligomycin to determine the contribution of TCA cycle-derived CO<sub>2</sub> in nonglycolytic acidification. Oligomycin further increased glycolytic capacity, and it was abolished by the addition of the inhibitor of glycolysis 2-DG. Interestingly, the glycolytic capacity of double knockout was much higher than those of other genotypes, with basal levels of both glycolysis and glycolytic reserve after 2-DG injection persisting at the increased (*P*-value < 0.0001) level. In the glucose oxidation test, the difference between the four genotypes (Supplemental Fig. 9B) reflected the difference observed in the basal respiration rates (Fig. 4D), as addition of glucose failed to increase the oxygen consumption rate (OCR) (data not shown). These results suggest that glycolysis accounts for the majority of the ECAR observed in MEFs and profoundly decreases in differentiating cells to the level observed in cells incapable of differentiation. Next, we asked whether the Kdm5a-dependent increase in the OCR was due to differences in utilization of fatty acids of various chain lengths, the major nutrient substrates in muscle tissue. We did not see OCR induction after glucose addition (data not shown), suggesting that none of our MEFs actively oxidize glucose. In contrast, MEFs exhibited active oxidation of fatty acids (FAO), as addition of butyrate or palmitate caused an increase in the OCR (Fig. 4E). When we compared the fold change in the OCR, we found that these fatty acids exhibited lower levels of oxidation in *Rb1*<sup>-/-</sup> MEFs. Metformin favors the mitochondrial FAO, and palmitate oxidation in differentiating C2C12 cells was increased after metformin treatment (Supplemental Fig. 9C). An increase in the OCR in response to acute palmitate addition was also specifically enhanced by metformin in *Kdm5a*<sup>-/-</sup> cells (Supplemental Fig. 9C). Metformin treatment resulted in the anticipated activation of AMP-activated protein kinase (AMPK), as evidenced by marked induction in one of its downstream targets, acetyl-CoA carboxylase (ACC) (Supplemental Fig. 9D). These findings indicate that one of the key metabolic consequences of *Kdm5a* loss during myogenesis is the propensity to increase FAO. Therefore, myogenic differentiation correlates with the increase in specific mitochondrial components and a shift to oxidative phosphorylation and oxidation of specific nutrients, a process that is impaired in *Rb1*<sup>-/-</sup> cells but restored in double-knockout cells.




**Figure 4.** Rescue of mitochondrial morphology and mitochondrial functions with *Kdm5a* knockout. (A) Comparison of induced MEFs of different genotypes reveals pRb and *Kdm5a* function in the mitochondrion. ICC for the RC component Cox IV and EM images are shown for four different genotypes. A representative mitochondrial structure for each class is circled in the zoomed panels. MEFs containing Lenti-CMV-MyoDER[T] [MyoDER[T]] lentiviruses were induced with 4-hydroxytamoxifen (OHT) for 72 h. (B) Quantitation of mitochondrial number and area (size) based on EM data. Mean  $\pm$  SEM for  $n \geq 5$  EM images ( $>100$  mitochondria per genotype). (\*)  $P < 0.05$  relative to *Rb1*<sup>-/-</sup>. (C) Selective mitochondrial components are rescued in induced double-knockout MEFs to the wild-type level. Immunoblot analysis was performed with the indicated antibodies from total cell extracts prepared from cells of four genotypes induced for 24 h and compared with the uninduced condition (0 h). (D) Kinetics of the OCR response to oligomycin to determine ATP-coupled respiration, FCCP to establish maximal respiratory capacity, and a mixture of antimycin and rotenone to determine mitochondrial respiration. MEFs of four genotypes were transduced with Lenti-empty vector (0 h) or Lenti-MyoD and induced for 18 h. Assays were performed using the XF<sup>96</sup> extracellular flux analyzer. Upon the completion of an assay, cells were lysed, and protein content was determined. Data were normalized to the protein content. (E) Substrate utilization in cells treated for 0 h and 18 h. The difference in OCR was measured acutely after injection of the short chain fatty acid butyrate or the long chain fatty acid palmitate by comparing the fourth and third measurements. Assays were performed as in D, and data are presented as a fold change relative to the 0-h wild-type MEFs. (\*\*\*)  $P < 0.0001$  is shown for double knockout relative to the *Rb1*<sup>-/-</sup>. In D and E, mean  $\pm$  SEM for  $n \geq 4$  replicate wells.

#### Intact mitochondrial function is intimately linked to differentiation potential

The top GO terms identified during myogenesis were muscle system and mitochondrion (Fig. 1D), distinguishing double-knockout MEFs, which are proficient in differentiation, oxidative phosphorylation, and activity of the

RCs, from *Rb1*<sup>-/-</sup> MEFs (Figs. 1B, 4D). Was the rescue of mitochondrial function a consequence or the cause of restoring myogenic differentiation? The intact mitochondrial functions are essential for myogenic differentiation in MEFs, as inhibitors of RCI rotenone, metformin, and phenformin as well as the inhibitor of RCIV sodium azide blocked myogenesis (Fig. 5A). The effect was not due





**Figure 5.** Intact mitochondrial function is necessary for differentiation. (A) Mitochondrial “poisons” inhibit differentiation. Rotenone blocks the ubiquinone-binding pocket of RCI, disrupting the first step in the RC reaction. Sodium azide inhibits RCIV by binding to the heme cofactor of cytochrome c. All cells were transduced with Adeno-MyoD and induced for 96 h. To rescue apoptosis, cells were transduced with Adeno-BCL2 where indicated. (B) Pgc-1 $\alpha$  (peroxisome proliferator-activated receptor  $\gamma$ -coactivator 1 $\alpha$ ; also called PPARGC1A) rescues the mitochondrial defect in  $Rb1^{-/-}$  cells. Cox IV staining was performed in  $Rb1^{-/-}$  cells that were transduced with lentiviral pRB or Pgc-1 $\alpha$  constructs or treated with HDAC inhibitors. A representative mitochondrial structure for each class is circled in the zoomed panels. (C) Quantitation of mitochondrial morphology in  $Rb1^{-/-}$  MEFs. Mean  $\pm$  SD for  $n = 5$  microscopic fields ( $\sim 100$  cells per experiment) in two representative experiments. Mitochondrial morphology is changed toward tubular morphology and large spheres in  $Rb1^{-/-}$  MEFs transduced with Pgc-1 $\alpha$  lentiviruses. Inhibition of Drp1 by treatment with the inhibitor Mdivi-1 results in changes toward tubular morphology and large spheres. (D) Loss of *Mfn2* by RNAi decreases the representation of large sphere/dense tubule mitochondria in induced double-knockout MEFs, similar to the overexpression of KDM5A. Wild-type cells and double-knockout cells with overexpression of the KDM5A demethylase mutant served as controls. (E) Quantitation of mitochondrial morphology in double-knockout MEFs. Double-knockout MEFs were transduced with lentiviruses expressing KDM5A derivatives, Mfn2, or shRNA to *Mfn2*. Mean  $\pm$  SD for  $n = 5$  microscopic fields ( $\sim 100$  cells per experiment) in two representative experiments. (F) Knockdown of *Mfn2* abrogates differentiation rescue in double knockout, while Mfn2 overexpression rescues differentiation from KDM5A inhibition. In B–F, MEFs were transduced with MyoDER[T] and analyzed after a 72-h OHT treatment. All images were generated by confocal microscopy. (G) Comparison of MyHC expression levels.  $Rb1^{-/-}$  cells prepared as in F were analyzed after a 72-h treatment with OHT, and wild-type and double-knockout cells were analyzed after a 48-h treatment with OHT. (ns)  $P > 0.1$ ; (\*\*)  $P < 0.001$ ; (\*\*\*)  $P < 0.0001$ , relative to the double-knockout vector control. Cells were analyzed for MyHC or Cox IV expression by ICC and confocal microscopy.

to apoptosis, as inhibition of apoptosis with BCL2 still failed induction of differentiation in MEFs treated with the inhibitors (Fig. 5A). Moreover, treatments with phenformin and metformin, nontoxic RCI inhibitors, did not induce apoptosis, as assessed by staining for cleaved Caspase 3 (Supplemental Fig. 9E). Although the effect of phenformin and metformin was weaker than the effect of rotenone, it still resulted in significant differentiation inhibition (Supplemental Fig. 9E,F). These results showed that functional mitochondria are necessary for myogenic differentiation.

Reintroduction of pRB in *Rb1*<sup>-/-</sup> cells rescued not only MyHC expression but also the mitochondrial phenotype (Fig. 5B,C). In contrast, introduction of KDM5A with intact demethylase function in double-knockout cells decreased the number of not only differentiated cells but also cells with normal mitochondria (Fig. 5D–G). Treatment of *Rb1*<sup>-/-</sup> cells with HDAC inhibitors had no effect (Fig. 5B,C). These experiments demonstrated that it was possible to correct the mitochondrial morphology along with promoting differentiation in *Rb1*<sup>-/-</sup> cells.

Mitochondrial morphology is determined by the balance between mitochondrial fusion and fission. The dense tubule networks and large spheres, which were observed in induced double-knockout compared with *Rb1*<sup>-/-</sup> MEFs (Fig. 4A), recognize a preference of fusion events (Chan 2012). Mfn2, a GTPase of the outer mitochondrial membrane, is commonly known for its regulatory role in mitochondrial fusion. *Mfn2* knockdown affected the prevalent mitochondrial phenotypes correlating with differentiation rescue, as transduction of double-knockout MEFs with sh*Mfn2* lentiviruses reduced Cox IV staining, which was similar to the KDM5A reintroduction (Fig. 5D–G). In contrast, cotransduction of *KDM5A* and *Mfn2* lentiviruses restored the number of dense tubules as well as differentiation, further suggesting that KDM5A inhibits Mfn2 function to repress differentiation. Excessive mitochondrial fission is common in human lung cancer cells, where it was shown to be due to imbalance in the expression of Mfn2 and the main regulator of mitochondrial fission Drp1 (Rehman et al. 2012). Therefore, as *Mfn2* is down-regulated in *Rb1*<sup>-/-</sup> cells (Fig. 4C), inhibition of Drp1 was attempted. Treatment of induced *Rb1*<sup>-/-</sup> cells with the Drp1 inhibitor Mdivi-1 increased large sphere/dense tubule formation (Fig. 5C). These findings demonstrate that *Rb1*<sup>-/-</sup> cells are responsive to modulation of mitochondrial fusion, and it is possible to at least partially restore the balance between mitochondrial fusion and fission toward the wild type.


#### Increased mitochondrial function rescues differentiation

We hypothesized that there is an intimate link between the failure of mitochondrial function and the failure of differentiation in *Rb1*<sup>-/-</sup> cells. *Rb1*<sup>-/-</sup> MEFs transduced with *Mfn2* lentiviruses were tested for MyHC gene expression. Mfn2 significantly rescued MyHC when compared with the empty vector and reintroduced pRB (Figs.

5F,G, 6A–C). Treatment with Mdivi-1 also increased MyHC expression, while DMSO treatment had no effect (Fig. 6C). In contrast, sh*Mfn2* resulted in impaired differentiation in double-knockout MEFs (Fig. 5F,G). As overexpression of Mfn2, a regulator of many other mitochondrial functions besides fusion, was sufficient for differentiation rescue, it is possible that redirecting energy metabolism away from glycolysis and toward the Krebs cycle and mitochondrial oxidative phosphorylation would have the same effect. However, treatment with inhibitors of glycolysis or with selective peroxisome proliferator-activated receptor agonists (see the Supplemental Material) failed to induce MyHC expression. Thus, rescue of pRB-mediated differentiation specifically requires rescue of mitochondrial functions.

As loss of Kdm5a, which directly inhibits multiple genes encoding mitochondrial proteins, rescued differentiation, we attempted to identify an alternative approach to restore this subset of Kdm5a targets through their ultimate regulatory transcriptional activator (Fig. 6D). In order to identify such a factor, we analyzed the TSSs of Kdm5a targets for possible occurrences of TF-binding motifs. Rb/E2f/Dp sites were enriched at cell cycle genes increased in *Rb1*<sup>-/-</sup> cells compared with the wild type, while muscle initiator sequence MINI, a motif commonly found in muscle genes, was characteristic of the genes decreased in *Rb1*<sup>-/-</sup> cells but not of the Kdm5a targets (Fig. 6E; Supplemental Table 4) as expected. Binding sites for eight different TFs—including Nrf1 and Nrf2 (major regulators of genes involved in mitochondrial biogenesis and oxidative phosphorylation), cAMP response element-binding protein (CREB), and Yin Yang 1 (Yy1)—were highly significantly enriched at the genes decreased in *Rb1*<sup>-/-</sup> cells as well as at the promoters of Kdm5a targets ( $P < 10^{-16}$ ) that were rescued in DKO-myo.

The activity of Nrf1, Nrf2, CREB, and Yy1 can be dramatically increased by direct interaction with peroxisome proliferator-activated receptor  $\gamma$ -coactivator 1 $\alpha$  (PPARGC1A/PGC-1 $\alpha$ ) (Liang and Ward 2006; Blättler et al. 2012). Pgc-1 $\alpha$  activity determines mitochondrial gene expression signature in differentiating mouse myoblast or intact muscle cells (Rangwala et al. 2010). In particular, the *Mfn2* and *Cox IV* genes are regulated by Pgc-1, and mice with knockout of *Pgc-1 $\beta$*  display reduced mitochondrial size, which was associated with reduced *Mfn2* expression (Puigserver et al. 1998; Liesa et al. 2008). Pgc-1 $\alpha$  and Pgc-1 $\beta$  stimulate mitochondrial biogenesis and respiration in muscle cells (Liesa et al. 2008; Wenz et al. 2008). Both Pgc-1 proteins were expressed in induced MEFs, with about log<sub>2</sub> 1.6-fold difference in the Pgc-1 $\alpha$  transcript in *Rb1*<sup>-/-</sup> compared with the double knockout and wild type (RNA-seq data GSE53528). Therefore, we reasoned that restoration of KDM5A target gene expression may be achieved through overexpression of the common coactivator of TFs identified in our TF-binding site (TFBS) study (Fig. 6E). Transduction of *Rb1*<sup>-/-</sup> MEFs with Pgc-1 $\alpha$  lentiviruses increased the number of cells with tubular mitochondria (Fig. 5C), suggesting that Pgc-1 $\alpha$  overexpression is sufficient for mitochondrial



**Figure 6.** Increased mitochondrial function rescues differentiation. (A) Immunoblot analysis of lysates prepared from cells expressing Flag-tagged proteins pRB, Mfn2, and Pgc-1α. (B) Differentiation rescue with mitochondrial regulators. Images of ICC for MyHC were generated using confocal microscopy. *Rb1*<sup>-/-</sup> MEFs containing MyoDER[T] lentiviruses were transduced with lentiviral vectors expressing pRB, Mfn2, and Pgc-1α proteins as in A or with the empty vector and induced with OHT. (C) Cells with increased mitochondrial function show high MyHC expression. MEFs containing MyoDER[T] were transduced with lentiviruses expressing the mitochondrial regulators or treated with 30 μM Drp1 inhibitor Mdivi-1. Empty vector or DMSO treatment was used as a control. Cells were analyzed after a 72-h treatment with OHT. Mean ± SD for the number of MyHC-positive cells with more than two nuclei in *n* = 5 microscopic fields (~100 nuclei per field) in *n* = 3 representative experiments; (\*\*\*) *P* < 0.001; (\*\*\*) *P* < 0.0001, relative to the vector. (D) Schematics of myogenic differentiation rescue. *Rb1*<sup>-/-</sup> cells carrying Lenti-MyoD (or MyoDER[T]) were transduced with lentiviruses that express the mitochondrial regulators, restoring the expression level of Kdm5a targets. (E) Occurrences of TF-binding sites (TFBSs) in the promoter regions of Kdm5a targets. Enriched TFBSs with corrected *P*-values of <10<sup>-16</sup>

are shown in the heat map, arranged in the order of significance for genes increased in *Rb1*<sup>-/-</sup> and for the Kdm5a target genes rescued in DKO-myoblasts. The whole list of enriched TFBSs with *P* < 0.02 is shown in Supplemental Table 4. (F) Pgc-1α specifically binds to the *Mfn2* promoter during differentiation. ChIP experiments in *Rb1*<sup>-/-</sup> cells that were transduced with Pgc-1α lentiviruses and analyzed at 0 h and 24 h after induction. *Igr2* is an intergenic control region. Mean ± SEM for *n* = 2 ChIP assays. (G) Expression level of MyHC is fully rescued by mitochondrial regulators. Immunoblot analysis of cell lysates prepared from *Rb1*<sup>-/-</sup> MEFs transduced with Lenti-MyoD and lentiviral vectors expressing pRB, Mfn2, or Pgc-1α and induced for 120 h.


morphology rescue. In fact, Pgc-1α binding to the *Mfn2* promoter highly enriched after induction of differentiation (Fig. 6F). Remarkably, when the multinucleation and expression of MyHC was examined in cells with Pgc-1α overexpression, it was very distinctive from the cells transduced with the control vector (Fig. 6B,C). Both Pgc-1α and Mfn2 phenocopied reintroduction of pRB in the level of MyHC expression (Fig. 6G). Therefore, overexpression of two different regulators that control a broad range of mitochondrial functions—mitofusin Mfn2 and the transcriptional coactivator Pgc-1α—restored the Rb-dependent differentiation.

#### Growth of human RB-negative cell lines is responsive to KDM5A and PGC-1α

The obtained results predict that induction of mitochondrial functions through epigenetic or metabolic modulation will drive differentiation in *RB1*<sup>-/-</sup> cancer cells. We tested this idea by performing experiments on *KDM5A* knockdown by shRNA and Pgc-1α overexpression in cell lines that were established from five different human tumors with inactivated pRB function (Supplemental Fig. 10). The analysis included the Y79 cell line derived from a 2-yr-old girl with familial retinoblastoma and the RB-355 cell line derived from a nonfamilial unilaterally af-

ected child. Remarkably, reduced proliferation was evident in all cancer cell lines that were transduced with *KDM5A* or Pgc-1α lentiviruses but not with the control lentiviruses (Fig. 7A,B). Osteosarcoma cell line SAOS-2, cervical carcinoma cell line C33A, and small-cell lung cancer (SCLC) cell line NCI-H446 displayed significant morphological changes with both *KDM5A* knockdown and Pgc-1α overexpression (Fig. 6A). This was consistent with the previous data, as SAOS-2 cells can be differentiated by a master regulator of osteoblast differentiation (RUNX2/CBFA1) along with reintroduction of pRB (Thomas et al. 2001) or *KDM5A* knockdown (Benevolenskaya et al. 2005). As a control for the C33A cell line, we used treatment with the antioxidant N-acetyl L-cysteine (NAC), which is known to induce keratinocyte differentiation in colon and ovarian cancer cell lines (Parasassi et al. 2005).

To evaluate cell differentiation potential and mitochondrial status, we performed RT-qPCR analysis from transduced cells. As Mfn2 expression correlates with the promotion of Rb-mediated myogenic differentiation in MEFs, we used it as a readout of mitochondrial dysfunction in *RB1*<sup>-/-</sup> cancer cells. *KDM5A* shRNA significantly increased the *MFN2* level in all examined cell lines (Fig. 7C,D). The NCI-H446 cell line contains subpopulations of neuroendocrine cells and cells with stem cell properties



**Figure 7.** Growth of human *RB*-negative cell lines is responsive to *KDM5A* RNA inhibition and *Pgc-1 $\alpha$*  overexpression. (A) Growth inhibition in *RB*-negative cell lines. SAOS-2 osteosarcoma, C33A cervical carcinoma, Y79 and RB-355 retinoblastoma cell lines, and the SCLC cell line H446 were transduced with lentiviruses encoding *KDM5A* shRNA and *Pgc-1 $\alpha$*  protein or with control lentiviruses. The NAC treatment, which was claimed to promote differentiation in several cancer cell models (Parasassi et al. 2005), was performed as another control along with the DMSO (vehicle) treatment. SAOS-2 were transfected with the master regulator of osteoblast differentiation *RUNX2/CBFA1* in order to induce the osteoblast differentiation (Thomas et al. 2001; Benevolenskaya et al. 2005). Representative images were acquired using a Zeiss microscope. (B) Proliferation assay for cells transduced with *KDM5A* shRNA or *Pgc-1 $\alpha$*  lentiviruses. Cell counting was performed at 2 and 4 d after plating of  $5 \times 10^4$  transduced cells. Mean  $\pm$  SD from two replicate wells. (C) *MFN2* mRNA level is up-regulated in *KDM5A* shRNA-treated cells. (D) Gene expression changes in the levels of specific mRNAs reflecting self-renewal and differentiation status and of *MFN2* mRNA in NCI-H446. Data for *KDM5A* shRNA-treated cells are in light colors, and data for cells transduced with *Pgc-1 $\alpha$*  lentiviruses are in dark colors. In C and D, gene expression was normalized relative to the *POLR1A* level and is shown compared with the control lentiviruses as mean  $\pm$  SEM for  $n = 2$  biological replicates.

(Calbo et al. 2011). The levels of specific mRNAs encoding neuronal, progenitor cell, and mesenchymal markers as well as self-renewal genes was significantly changed in cells with *KDM5A* shRNA and *Pgc-1 $\alpha$*  overexpression

(Fig. 7D). Thus, *KDM5A* and *Pgc-1 $\alpha$*  affect cell growth of *RB*-deficient human cancer cells, and decreasing heterogeneity of SCLC cell population indicates a shift to a more differentiated phenotype.

## Discussion

The inability of cells to execute their full differentiation potential is a hallmark of cancer. Despite the existence of multiple cancer subtypes, the pRB tumor suppressor function is lost in the majority of human cancers, suggesting that pRB carries a number of essential functions that are shared by most tumors. Here we describe a pRB function in promoting differentiation that is independent of its well-established role in the cell cycle regulation. Our data show that the differentiation block observed in *Rb*-deficient cells may be explained by the repression of genes encoding mitochondrial proteins by the histone demethylase *Kdm5a*. pRB directly binds to and activates the *Kdm5a* targets with mitochondrial functions, resulting in the rescue of mitochondrial biological processes in cells lacking both pRb and *Kdm5a*. *Kdm5a* removal from genes encoding mitochondrial proteins occurs early during differentiation and is required for the activation of differentiation markers. Significantly, the differentiation rescue can be achieved through a bona fide transcriptional regulator of mitochondrial genes, showing that an increase in mitochondrial function is sufficient for induction of differentiation in cells lacking pRB.

Previous studies have attributed the reluctance of *Rb*-negative cells to undergo differentiation to the role of pRb as an activator of positive differentiation regulators. pRb directly activates the basic helix–loop–helix (bHLH) protein NeuroD1 (Batsche et al. 2005) and serves a coactivator role to CBFA1 (Thomas et al. 2001). pRb may promote activation of differentiation markers through degradation of the E1A-like inhibitor of differentiation 1 (EID-1) (Miyake et al. 2000) or inhibition of the bHLH protein Id2 (Iavarone et al. 2004) that restricts activity of other bHLH as well as Ets and Pax families of TFs. Although these experiments provided important insights into cell type-specific roles of pRB and the fundamental mechanisms of differentiation, they were typically limited to the study of biological processes that were necessary but not sufficient to rescue differentiation. *Kdm5a* bound to certain genes associated with differentiation and was displaced from their promoters by pRB (Benevolenskaya et al. 2005). This would suggest that pRB is playing a role in sequestering KDM5A from developmental genes, thus explaining the rescue of differentiation in cells lacking both *Rb* and *Kdm5a*. However, at odds with this simplistic model were data from ChIP-seq and RNA-seq studies revealing that expression of *Kdm5a*-bound developmental genes was generally not restored by the *Kdm5a* loss. Instead, the rescued GOs represented genes with functions in the mitochondrion. Enhancing mitochondrial biogenesis restored differentiation in a manner similar to *Kdm5a* loss, thus providing further evidence for the central role of mitochondrial function as a mediator of differentiation.

pRb function in mitochondrial gene expression has been previously described during erythropoiesis, where the up-regulation of mitochondrial biogenesis was linked to a cellular exit from the cell cycle (Sankaran et al. 2008). Because terminal differentiation in erythroblasts occurs concomitantly with the cell cycle exit, the requirement

of mitochondrial burst specifically for differentiation could not be addressed. Our in vitro study using primary embryonic fibroblasts allowed us to distinguish cell cycle arrest from the expression of myogenic genes and acquisition of skeletal muscle structures. The muscle gene expression and multinucleation, but not the cell cycle exit, were rescued in *Rb1*<sup>-/-</sup> cells even with the deletion of only a single *Kdm5a* allele. In fact, a characteristic of differentiation induced upon combined *Rb1* and *Kdm5a* loss in MEFs was the exacerbated cell cycle re-entry. A large number of E2F direct targets were deregulated in DKO-myo, consistent with the role of KDM5A, pRB, and E2F family proteins in repression of cell cycle genes in terminally differentiated cells (Beshiri et al. 2012). However, a common feature in differentiating erythroblasts, skeletal muscle cells, and adipocytes was the mitochondrial burst, which was not restricted to erythroblast maturation to provide high-level heme biosynthesis and increased ATP production for globin synthesis. These findings are not in contradiction to the previously reported role of pRB in highly specialized tissue functions, such as in adaptive thermogenesis in brown adipose tissue (Hansen et al. 2004). It is conceivable that the differentiation block of mitochondrial function released by pRB, while occurring in a cell type-specific manner, is as common in living cells as the pRB-mediated cell cycle control.

The dependence of differentiation rescue in *Rb1*<sup>-/-</sup> cells on the mitochondrial GO and its independence of E2F-dependent GOs changes the way we prioritize pRB functions in gene regulation and tumorigenesis. In accordance with our observations, Dyson's group (Nicolay et al. 2015) discovered that the extensive proteomic changes commonly occurring in *Rb1*<sup>-/-</sup> tissues affect proteins of the mitochondrion but not of the E2F target genes. The decrease in mitochondrial components observed in mouse tissues had an effect on both TCA cycle and oxidative phosphorylation that was independent of cell cycle withdrawal, similar to our in vitro model. Differentiation promotion thus represents a functional aspect of pRB regulation of the mitochondrion. This may help explain a recently established role of pRb in lineage commitment and cell fate determination (Calo et al. 2010). As mitochondrial function depends on pRB in different tissues, *Rb* loss may affect stem cell and progenitor cell populations in multiple tissues.

Our data imply that the release of differentiation block at the mitochondrial level can be achieved through changes in the activity of TFs directly regulating genes of the mitochondrion. Upon induction of myogenic differentiation in wild-type cells, pRb was recruited to genes encoding mitochondrial proteins such as *Mfn2*. This occurred along with the dissociation of *Kdm5a*, which correlated with the increased TSS enrichment for H3K4me3 and was required for increased *Mfn2* expression. This mechanism explains why genes fail to activate in *Rb1*<sup>-/-</sup> cells (i.e., pRb playing a positive role) but become rescued by *Kdm5a* loss in double-knockout cells (i.e., *Kdm5a* playing a negative role). It is likely that *Kdm5a* is one of many transcriptional regulators of *Mfn2*, as the expression pattern of *Mfn2* during differentiation is complex, with

gene repression followed by gene activation (Lopez-Bigas et al. 2008). Consistent with this idea, the TFBS analysis predicted other TFs involved in the regulation of pRB-dependent genes like *Mfn2*. Importantly, the identified TFs are playing a critical role in mitochondrial function in *Rb1*<sup>-/-</sup> cells, as mitochondrial morphology was significantly improved in *Rb1*<sup>-/-</sup> MEFs that were induced for differentiation after overexpression of their common coactivator, Pgc-1 $\alpha$ . While we identified Pgc-1 $\alpha$  as a molecular mechanism for inducing differentiation through normalizing mitochondrial activity, Pgc-1 $\alpha$  has a specific role in type I skeletal muscle (Liang and Ward 2006), indicating that other mitochondrial regulators may be more effective in other cell types. Recent studies on cardiomyocyte differentiation established the link between *Mfn2* and Notch signaling (Kasahara et al. 2013). Consistent with this result, our RNA-seq data (GSE53528 with full gene list) show that Notch targets, genes involved in calcium-regulated signaling, and the gene encoding *Mef2* are rescued in double-knockout MEFs. Whether the functional connection between *Mfn2* and transcriptional nodes downstream from Notch signaling exists in all muscle cells and whether a calcium excitation transcription coupling generally operates during differentiation are highly speculative ideas at this point.

The respiratory capacity of the mitochondria during myogenic differentiation seems to be positively impacted by an increased mitochondrial fusion. Induced *Rb1*<sup>-/-</sup> MEFs had small mitochondria with distinctive Cox IV and *Mfn2* expression. In contrast, induced double-knockout MEFs had mitochondrial morphology that was similar to the wild-type MEFs, and the mitochondria were rescued functionally; i.e., for RC activity and ATP production. Although *Mfn2* is mostly known for its role in mitochondrial fusion, it also activates mitochondrial metabolism and increases the RC expression (Pich et al. 2005). Specifically, *mfn2* loss in skeletal muscle was characterized by reduced RC expression level and activity and impaired respiratory function (Segalés et al. 2013). A loss of *Kdm5a* in *Rb1*<sup>-/-</sup> MEFs resulted in a significant shift from glycolytic to oxidative metabolism. MEFs lacking *Kdm5a* still had the highest glycolytic capacity, which seemingly did not interfere with successful differentiation. In response to acute glucose addition, the OCR not only failed to increase but in fact decreased, probably due to the Crabtree effect. Other substrate utilization experiments showed that cells lacking *Kdm5a* have a high rate of FAO, which can be further increased by pretreatment with metformin. Currently proposed mechanisms for metformin are consistent with not only the direct inhibition of RCI but also the stimulation of glucose uptake and FAO, which include activating AMPK. KDM5A loss results in increased phosphorylation of AMPK at T172 (Tzatsos et al. 2013). This suggests that *Kdm5a*<sup>-/-</sup> and double-knockout MEFs may have downstream consequences of the *Kdm5a* target gene up-regulation for sensing cellular energy status.

While molecular and chemical inhibition of fission promoted differentiation, further analysis will show to what extent increased mitochondrial fusion phenocopies the ef-

fect of a *Kdm5a* loss. Although restoration of the pRB-dependent mitochondrial function is both necessary and sufficient for the differentiation rescue in vitro, it is conceivable that *Kdm5a* is playing an additional pRB-dependent role as a repressor or activator of developmental genes. In particular, KDM5A has a direct effect on TF activity at some pRB target promoters; this may contribute to the characteristic morphological changes reminiscent of the effects seen by reintroducing pRB (Benevolenskaya et al. 2005). *Kdm5a* deletion failed to rescue the embryonic lethality of *Rb1*<sup>-/-</sup> mice and resulted in a twofold reduction in the number of *Rb1*<sup>+/-</sup> pups born (Lin et al. 2011), indicating that *Kdm5a* loss can accelerate embryonic defects in animals lacking *Rb1*.

As an indication that a *Kdm5a*-directed mechanism prevails in tumor suppression by pRB, data in knockout mice showed that the pituitary and thyroid tumors that normally spontaneously developed in *Rb1*<sup>+/-</sup> mice were unable to progress in *Kdm5a*<sup>-/-</sup>; *Rb1*<sup>+/-</sup> mice (Lin et al. 2011). Thus, genetic loss of *Kdm5a* results in the inhibition of tumor progression and the extension of cancer-free survival. Whether this was due to the rescued expression of mitochondrial proteins and/or differentiation remains to be tested. In particular, enhancing the mitochondrial network formation was shown to have a tumor-suppressive role, as injection of either MFN2-encoding adenovirus or Mdivi-1 in a lung adenocarcinoma xenograft model significantly reduced tumor volume (Rehman et al. 2012). However, there is no reason to believe that metabolic function of the RB pathway is restricted by regulation of KDM5A target genes. pRB is required for increased glycolysis and mitochondrial oxidative phosphorylation in cells that have undergone oncogene-induced senescence (Takebayashi et al. 2015). Intriguingly, the responsible mechanism may include changes in catalytic activity of histone-modifying enzymes, like the KDM5 family. In addition to pRB, other RB family members, upstream regulators of pRB, and E2F family proteins may directly regulate metabolism in order to maintain cellular homeostasis or drive cell proliferation, differentiation, and survival (Macleod 2008; Nicolay and Dyson 2013; Benevolenskaya and Frolov 2015). In particular, E2f1 orchestrates not only a proliferative response but also a metabolic response in conditions requiring adaptations to new energy demands (e.g., fasting and cold) (Blanchet et al. 2012).

Proliferation control by pRB has been considered central in its tumor suppression, although additional roles of pRB in apoptosis, maintenance of genome stability, and cellular senescence have also been described (Narita et al. 2003; Dick and Rubin 2013; Hilgendorf et al. 2013). Therefore, cytotoxic drugs used in chemotherapy were designed to arrest dividing cells by inducing DNA damage or targeting products of E2F-dependent genes (Whitfield et al. 2006). Mutations in mitochondrial proteins are rare in cancer cells, arguing the importance of mitochondrial functions in tumorigenesis. However, the direct link of mutated pRB to transcriptional regulation of genes encoding mitochondrial proteins that we described suggests that the impaired oxidative metabolism

results from an inactivation of pRB, which is common in human tumors. As we found in *Rb1*<sup>-/-</sup> MEFs, moderate gene expression changes are likely reflective of severe mitochondrial and metabolic defects. The impairment of mitochondrial functions in *Rb*-negative cancer cells is not detrimental to cancer cell growth, suggesting that targeting dysfunctional mitochondria is not an easy task. Cells continue to engage in glycolysis and lactate production even under conditions of high oxygen, known as the Warburg effect; in addition, they adapt glutamine-dependent reductive carboxylation [Nicolay et al. 2013]. However, the link between mitochondrial function and differentiation and its separation from cell cycle regulation may have implications in developing restorative, differentiation-based therapies.

In exploring a therapeutic strategy for the activation of mitochondrial function in order to differentiate cells derived from *Rb*-deficient tumors, we manipulated KDM5A and PGC-1 $\alpha$  level in four main human cancer types with pRB inactivation. Both KDM5A shRNA and PGC-1 $\alpha$  overexpression resulted in reduced cell growth in osteosarcoma, cervical carcinoma, retinoblastoma, and SCLC cell lines. Differentiation of retinoblastoma cell lines is manifested in increased cell adhesion and requires special techniques that were not applied in our analysis by light microscope [Laurie et al. 2009]. However, in cases with the KDM5A knockdown, we recorded increased *MFN2* expression, indicating that retinoblastoma cells respond to KDM5A loss by increasing mitochondrial fusion protein similar to other cell types. Importantly, KDM5A loss reduced the heterogeneity in SCLC, which remains the main challenge for cancer therapy, resulting in a high mortality rate in SCLC patients. Almost 95% of SCLC cell lines have alterations in the *RB1* gene [Blanco et al. 2009], underscoring the importance of identification of downstream *RB1* effectors for the development of successful SCLC drug therapies. Our work establishes the KDM5A metabolic axis as a critical mediator of the tumor-promoting effects secondary to pRB loss. This allows for the development of novel therapeutic approaches that diminish the aggressiveness of RB-deficient tumors by restoring their differentiation potential and could thus be used alongside existing cancer therapies targeting the cell cycle to augment their efficacy. The involvement of KDM5A and/or mitochondrial functions in determining the differentiation status can be further tested in vivo using recently generated mouse models of highly aggressive SCLC [Gazdar et al. 2015]. Moreover, peculiarities of the mitochondrial response in RB-deficient tumors compared with normal tissue and RB-positive tumors are poorly understood. Exploiting anti-cancer agents for their effect on mitochondrial functions in tissues with different pRB statuses will thus be beneficial. Furthermore, KDM5A may represent an epigenetic regulator controlling the metabolic program that synchronizes energy homeostasis with a differentiation signal. In this regard, inhibition of KDM5A also provides a potential node for therapeutic intervention for diseases associated with reduced oxidative metabolism and a lower type I fiber content in skeletal muscle, such as cachexia and obesity.

## Materials and methods

### Cell culture and differentiation

MEFs were isolated from wild-type, *Kdm5a*<sup>-/-</sup>, and double-knockout littermates and from *Rb1*<sup>-/-</sup> embryos at the same genetic background as described [Lin et al. 2011]. Adenoviral transductions were performed in a DM containing DMEM (CellGro), 2% horse serum (Gibco), and 10  $\mu\text{g mL}^{-1}$  insulin from bovine pancreas (Sigma). After 18 h of incubation, the DM containing viruses was replaced with fresh DM. Lentiviral transductions were performed in DMEM growth medium (GM) containing 7.5  $\mu\text{g mL}^{-1}$  polybrene (Sigma). GM was replaced with DM to induce differentiation 24–48 h afterward. For the differentiation of cells stably transduced with the inducible MyoD MyoDER[T], cells were first treated with DM containing 100 nM 4-hydroxytamoxifen (OHT), which, after 24 h, was replaced on DM without OHT. For the rescue experiments, *Rb1*<sup>-/-</sup> MEFs were first transduced with Lenti-CMV-MyoD or MyoDER[T] overnight as above. After that, cells were washed twice with PBS, medium was replaced with fresh GM, and, 8 h later, the second transduction with corresponding pLenti-CMV-Hygro-3xFlag lentiviruses was performed overnight. The medium was changed on GM for 2 h to allow cells recover, and then induction was started in DM supplemented with OHT if necessary. C2C12 myoblast cells were maintained in DMEM containing 20% FBS and induced in DM containing 2% horse serum and 10  $\mu\text{g mL}^{-1}$  insulin. Induction of adipogenic differentiation was performed as described previously [Benevolenskaya et al. 2005]. Cell lines were purchased from the American Type Culture Collection, and the RB-355 cell line was kindly provided by Dr. M.A. Dyer [Stewart et al. 2015].

### RNA isolation and RNA-seq

Cells were induced for differentiation for 96 h as above with the following modifications. Cells of each genotype were plated at  $2.5 \times 10^5$  cells per well in eight wells on 12-well dishes for RNA isolation from total cell population and on six-well dishes when the protocol involved purification of myotubes. The following day, the cells were transduced with Adeno-MyoD ( $2.2 \times 10^8$  plaque-forming units [PFU] per well). Each cDNA library was prepared from the pool of four wells. RNA was extracted with Trizol (Invitrogen) and purified by loading the aqueous phase containing the RNA premixed 1:1 with 70% ethanol on Qiagen RNeasy Micro (Qiagen, catalog no. 217084) column according to the Qiagen protocol. For mRNA (used for wild-type and double-knockout genotypes), 1.5  $\mu\text{g}$  of RNA from each sample was subjected to two rounds of Oligo-dT purification with Dynal Oligo-dT beads (Invitrogen). For RiboMinus RNA (used for wild-type, *Kdm5a*<sup>-/-</sup>, *Rb1*<sup>-/-</sup>, and double-knockout genotypes), 1.7  $\mu\text{g}$  of total RNA from each sample was processed using the RiboMinus eukaryote kit for RNA-seq (Ambion, catalog no. A10837-08) according to the Ambion protocol. RNA-seq counts represent baseMean values in Supplemental Table 1. The full data are deposited under GSE53528.

### Functional enrichment analysis

Functional annotation of target genes was based on GO biological process or cellular location (<http://www.geneontology.org>). Analysis for differentially expressed genes was based on the Goseq package [Young et al. 2010]. Resulting *P*-values were adjusted for multiple testing using Benjamin and Hochberg's method of false discovery rate (FDR) [Benjamini and Hochberg 1995]. The

heat map of corrected *P*-values was generated using GiTools (Perez-Llamas and Lopez-Bigas 2011).

#### Enrichment of TF binding

The occurrence of TF motifs in the promoter regions (600 base pairs [bp] upstream with 200 bp downstream with respect to the TSS) were predicted using the STORM algorithm (Schones et al. 2007) with a *P*-value cutoff of 0.0000125 as well as position frequency matrices (PFMs) from the TRANSFAC database (professional version release 2009.4) (Matys et al. 2003). Analysis of overrepresentation of the identified putative TF motifs on DE gene promoters against all promoters as background (i.e., enrichment of TF binding) was carried out using Gitools (Perez-Llamas and Lopez-Bigas 2011). FDR-corrected *P*-values (Benjamini and Hochberg 1995) were used for the heat map representation of enriched TFs.

#### ChIP-seq data

H3K4me3 ChIP-seq was performed in *Kdm5a<sup>fl/fl</sup>* and *Kdm5a<sup>-/-</sup>* (with deleted *Kdm5a* alleles) embryonic stem (C57BL/6) cells. ChIP was performed with rabbit anti-H3K4me3 antibody (Millipore, 07-473) following our established protocol (Beshiri et al. 2010). The data have been deposited under GSE28348. Genomics targets for *Kdm5a* came from our previous study (Beshiri et al. 2012), and targets for *E2F4* came from GSM516408 (Kim et al. 2010). ChIP-seq data for pRB (GSM497489) (Chicas et al. 2010) were processed from raw source data. Peak caller algorithm MACS (version 1.3.7.1) (Zhang et al. 2008) was used to determine the enriched peak regions. Enriched peaks were annotated to the nearest EnsEMBL gene using the Bioconductor package ChIPpeakAnno (Zhu et al. 2010). Human genes were converted to mouse orthologs using EnsEMBL Biomart. Data were annotated with the University of California at Santa Cruz mouse reference genome (mm9) (Mouse Genome Sequencing Consortium 2002).

#### Acknowledgments

We thank W. Kaelin Jr., N. Dyson, and B. Nicolay for the discussion and comments on the manuscript. We are grateful to K. Macleod for providing additional *Rb1<sup>-/-</sup>* MEFs, M.A. Dyer for the retinoblastoma RB-355 cells, and A. Vilcova for the generation of lentiviral constructs in destination vectors. This work was supported by R01CA138631 (to E.V.B.) and R01GM094220 (to J.R.) from the National Institutes of Health, educational grant SAF2009-06954 (to N.L.-B.) from the Spanish Ministry of Science, and a fellowship from the Agencia de Gestió d'Ajuts Universitaris i de Recerca of the Catalanian Government, Spain (to A.B.M.M.K.I.).

#### References

Batsche E, Moschopoulos P, Desroches J, Bilodeau S, Drouin J. 2005. Retinoblastoma and the related pocket protein p107 act as coactivators of NeuroD1 to enhance gene transcription. *J Biol Chem* **280**: 16088–16095.

Benevolenskaya EV, Frolov MV. 2015. Emerging links between E2F control and mitochondrial function. *Cancer Res* **75**: 619–623.

Benevolenskaya EV, Murray HL, Branton P, Young RA, Kaelin WG. 2005. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. *Mol Cell* **18**: 623–635.

Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B* **57**: 289–300.

Berkes CA, Tapscott SJ. 2005. MyoD and the transcriptional control of myogenesis. *Semin Cell Dev Biol* **16**: 585–595.

Beshiri ML, Islam A, Dewaal DC, Richter WF, Love J, Lopez-Bigas N, Benevolenskaya EV. 2010. Genome-wide analysis using ChIP to identify isoform-specific gene targets. *JoVE* **41**: 2101.

Beshiri ML, Holmes KB, Richter WF, Hess S, Islam ABMMK, Yan Q, Plante L, Litovchick L, Gévry N, Lopez-Bigas N, et al. 2012. Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation. *Proc Natl Acad Sci* **109**: 18499–18504.

Blais A, van Oevelen CJC, Margueron R, Acosta-Alvear D, Dynlacht BD. 2007. Retinoblastoma tumor suppressor protein-dependent methylation of histone H3 lysine 27 is associated with irreversible cell cycle exit. *J Cell Biol* **179**: 1399–1412.

Blanchet E, Annicotte JS, Pradelli LA, Hugon G, Matecki S, Morinet D, Rivier F, Fajas L. 2012. E2F transcription factor-1 deficiency reduces pathophysiology in the mouse model of Duchenne muscular dystrophy through increased muscle oxidative metabolism. *Hum Mol Genet* **21**: 3910–3917.

Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R, Montuenga LM, Minna JD, Yokota J, Sanchez-Cespedes M. 2009. A gene-alteration profile of human lung cancer cell lines. *Hum Mutat* **30**: 1199–1206.

Blättler SM, Verdegue F, Liesa M, Cunningham JT, Vogel RO, Chim H, Liu H, Romanino K, Shirihai OS, Vazquez F, et al. 2012. Defective mitochondrial morphology and bioenergetic function in mice lacking the transcription factor YY1 in skeletal muscle. *Mol Cell Biol* **32**: 3333–3346.

Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, Berns A. 2011. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. *Cancer Cell* **19**: 244–256.

Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. 2010. Rb regulates fate choice and lineage commitment in vivo. *Nature* **466**: 1110–1114.

Chan DC. 2012. Fusion and fission: interlinked processes critical for mitochondrial health. *Annu Rev Genet* **46**: 265–287.

Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M, Lowe SW. 2010. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. *Cell* **141**: 376–387.

Ciavarrá G, Ho AT, Cobrinik D, Zacksenhaus E. 2011. Critical role of the Rb family in myoblast survival and fusion. *PLoS One* **6**: e17682.

de Bruin A, Wu L, Saavedra HI, Wilson P, Yang Y, Rosol TJ, Weinstein M, Robinson ML, Leone G. 2003. Rb function in extra-embryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice. *Proc Natl Acad Sci* **100**: 6546–6551.

Dick FA, Rubin SM. 2013. Molecular mechanisms underlying RB protein function. *Nat Rev Mol Cell Biol* **14**: 297–306.

Frolov MV, Dyson NJ. 2004. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. *J Cell Sci* **117**: 2173–2181.

Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, MacPherson D, McFadden DG, Farago A, Jacks T, et al. 2015. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. *J Thorac Oncol* **10**: 553–564.

Hansen JB, Jørgensen C, Petersen RK, Hallenborg P, De Matteis R, Bøye HA, Petrovic N, Enerbäck S, Nedergaard J, Cinti S, et al. 2004. Retinoblastoma protein functions as a molecular switch



- determining white versus brown adipocyte differentiation. *Proc Natl Acad Sci* **101**: 4112–4117.
- Hilgendorf KI, Leshchiner ES, Nedelcu S, Maynard MA, Calo E, Ianari A, Walensky LD, Lees JA. 2013. The retinoblastoma protein induces apoptosis directly at the mitochondria. *Genes Dev* **27**: 1003–1015.
- Iavarone A, King ER, Dai X-M, Leone G, Stanley ER, Lasorella A. 2004. Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. *Nature* **432**: 1040–1045.
- Kasahara A, Cipolat S, Chen Y, Dorn GW, Scorrano L. 2013. Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. *Science* **342**: 734–737.
- Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH. 2010. A myc network accounts for similarities between embryonic stem and cancer cell transcription programs. *Cell* **143**: 313–324.
- Laurie N, Mohan A, McEvoy J, Reed D, Schweers B, Ajioka I, Valentine V, Dyer MA. 2009. Changes in retinoblastoma cell adhesion associated with optic nerve invasion. *Mol Cell Biol* **29**: 6268–6282.
- Liang H, Ward WF. 2006. PGC-1: a key regulator of energy metabolism. *Adv Physiol Educ* **30**: 145–151.
- Liesa M, Borda-d'Água B, Medina-Gómez G, Lelliott CJ, Paz JC, Rojo M, Palacín M, Vidal-Puig A, Zorzano A. 2008. Mitochondrial fusion is increased by the nuclear coactivator PGC-1 $\beta$ . *PLoS One* **3**: e3613.
- Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, et al. 2011. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. *Proc Natl Acad Sci* **108**: 13379–13386.
- Lopez-Bigas N, Kisiel TA, Dewaal DC, Holmes KB, Volkert TL, Gupta S, Love J, Murray HL, Young RA, Benevolenskaya EV. 2008. Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. *Mol Cell* **31**: 520–530.
- Macleod K. 1999. pRb and E2f-1 in mouse development and tumorigenesis. *Curr Opin Genet Dev* **9**: 31–39.
- Macleod KF. 2008. The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system. *Nat Rev Cancer* **8**: 769–781.
- MacPherson D, Sage J, Crowley D, Trumpp A, Bronson RT, Jacks T. 2003. Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. *Mol Cell Biol* **23**: 1044–1053.
- Manning AL, Longworth MS, Dyson NJ. 2010. Loss of pRB causes centromere dysfunction and chromosomal instability. *Genes Dev* **24**: 1364–1376.
- Matys V, Fricke E, Geffers R, Gössling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, et al. 2003. TRANSFAC: transcriptional regulation, from patterns to profiles. *Nucleic Acids Res* **31**: 374–378.
- Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR, Gan J, DeCaprio JA, Adams PD, Kaelin WG. 2000. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. *Mol Cell Biol* **20**: 8889–8902.
- Mouse Genome Sequencing Consortium. 2002. Initial sequencing and comparative analysis of the mouse genome. *Nature* **420**: 520–562.
- Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Specator DL, Hannon GJ, Lowe SW. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* **113**: 703–716.
- Nicolay BN, Dyson NJ. 2013. The multiple connections between pRB and cell metabolism. *Curr Opin Cell Biol* **25**: 735–740.
- Nicolay BN, Gameiro PA, Tschöp K, Korenjak M, Heilmann AM, Asara JM, Stephanopoulos G, Iliopoulos O, Dyson NJ. 2013. Loss of RBF1 changes glutamine catabolism. *Genes Dev* **27**: 182–196.
- Nicolay BN, Danielian PS, Kottakis F, Lapek JD Jr, Sanidas I, Miles WO, Dehnad M, Tschöp K, Gierut JJ, Manning AL, et al. 2015. Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation. *Genes Dev* (this issue). doi: 10.1101/gad.264127.115.
- Novitsch BG, Mulligan GJ, Jacks T, Lassar AB. 1996. Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. *J Cell Biol* **135**: 441–456.
- Parasassi T, Brunelli R, Bracci-Laudiero L, Greco G, Gustafsson AC, Krasnowska EK, Lundeberg J, Lundeberg T, Pittaluga E, Romano MC, et al. 2005. Differentiation of normal and cancer cells induced by sulfhydryl reduction: biochemical and molecular mechanisms. *Cell Death Differ* **12**: 1285–1296.
- Perez-Llamas C, Lopez-Bigas N. 2011. Gitoools: analysis and visualisation of genomic data using interactive heat-maps. *PLoS One* **6**: e19541.
- Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, Palacín M, Zorzano A. 2005. The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. *Hum Mol Genet* **14**: 1405–1415.
- Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* **92**: 829–839.
- Rangwala SM, Wang X, Calvo JA, Lindsley L, Zhang Y, Deyneko G, Beaulieu V, Gao J, Turner G, Markovits J. 2010. Estrogen-related receptor is a key regulator of muscle mitochondrial activity and oxidative capacity. *J Biol Chem* **285**: 22619–22629.
- Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. 2012. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. *FASEB J* **26**: 2175–2186.
- Sankaran VG, Orkin SH, Walkley CR. 2008. Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis. *Genes Dev* **22**: 463–475.
- Schones DE, Smith AD, Zhang MQ. 2007. Statistical significance of cis-regulatory modules. *BMC Bioinformatics* **8**: 19.
- Segalés J, Paz JC, Hernández-Alvarez MI, Sala D, Muñoz JP, Noguera E, Pich S, Palacín M, Enríquez JA, Zorzano A. 2013. A form of mitofusin 2 (Mfn2) lacking the transmembrane domains and the COOH-terminal end stimulates metabolism in muscle and liver cells. *Am J Physiol Endocrinol Metab* **305**: E1208–E1221.
- Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, Dyer MA. 2015. The Childhood Solid Tumor Network: a new resource for the developmental biology and oncology research communities. *Dev Biol* doi: 10.1016/j.ydbio.2015.03.001.
- Takebayashi S-I, Tanaka H, Hino S, Nakatsu Y, Igata T, Sakamoto A, Narita M, Nakao M. 2015. Retinoblastoma protein promotes oxidative phosphorylation through upregulation of glycolytic genes in oncogene-induced senescent cells. *Aging Cell* **14**: 689–697.
- Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW. 2001. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. *Mol Cell* **8**: 303–316.
- Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G, Wong K-K, Lan F, Trojer P, Park PJ, et al. 2013. KDM2B promotes pancreatic cancer via Polycomb-dependent and

- independent transcriptional programs. *J Clin Invest* **123**: 727–739.
- van Oevelen C, Wang J, Asp P, Yan Q, Kaelin WG Jr, Kluger Y, Dynlacht BD. 2008. A role for mammalian Sin3 in permanent gene silencing. *Mol Cell* **32**: 359–370.
- Wenz T, Diaz F, Spiegelman BM, Moraes CT. 2008. Activation of the PPAR/PGC-1 $\alpha$  pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. *Cell Metab* **8**: 249–256.
- Whitfield ML, George LK, Grant GD, Perou CM. 2006. Common markers of proliferation. *Nat Rev Cancer* **6**: 99–106.
- Wu L, de Bruin A, Saavedra HI, Starovic M, Trimboli A, Yang Y, Opavska J, Wilson P, Thompson JC, Ostrowski MC, et al. 2003. Extra-embryonic function of Rb is essential for embryonic development and viability. *Nature* **421**: 942–947.
- Young MD, Wakefield MJ, Smyth GK, Oshlack A. 2010. Gene ontology analysis for RNA-seq: accounting for selection bias. *Genome Biol* **11**: R14.
- Zacksenhaus E, Jiang Z, Chung D, Marth JD, Phillips RA, Gallie BL. 1996. pRb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. *Genes Dev* **10**: 3051–3064.
- Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nussbaum C, Myers RM, Brown M, Li W, et al. 2008. Model-based analysis of ChIP-seq (MACS). *Genome Biol* **9**: R137.
- Zhu LJ, Gazin C, Lawson ND, Pagès H, Lin SM, Lapointe DS, Green MR. 2010. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. *BMC Bioinformatics* **11**: 237.